PURPLE BIOTECH LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.1 ILa | -3.72% |
|
-25.82% | -43.26% |
| Mar. 14 | Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology | CI |
| Mar. 05 | Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 12.67M 4.78B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 20 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.59% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.72% | ||
| 1 week | -25.82% | ||
| Current month | -26.72% | ||
| 1 month | -32.46% | ||
| 3 months | -26.42% | ||
| 6 months | -68.36% | ||
| Current year | -43.26% |
1 week
17.80
25.50
1 month
17.8028.80
Current year
17.8033.60
1 year
17.8078.70
3 years
17.80203.20
5 years
17.80510.00
10 years
17.8016 926.00
| Managers | Title | Age | Since |
|---|---|---|---|
Gil Efron
CEO | Chief Executive Officer | 57 | 18-10-10 |
Lior Fhima
DFI | Director of Finance/CFO | - | 22-11-01 |
Ido Morpurgo
COO | Chief Operating Officer | 51 | 20-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eric Rowinsky
CHM | Chairman | 67 | 19-10-01 |
Yael Margolin
BRD | Director/Board Member | 70 | Dec. 19 |
Simcha Rock
BRD | Director/Board Member | 73 | 13-07-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 18.1 | -3.72% | 279,020 |
| 24-04-17 | 18.8 | -15.70% | 1,399,223 |
| 24-04-16 | 22.3 | -3.46% | 291,453 |
| 24-04-15 | 23.1 | -1.70% | 398,553 |
| 24-04-14 | 23.5 | -3.69% | 90,380 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 18, 2024 at 10:24 am EDT
More quotes
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -43.26% | 12.67M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -0.99% | 21.66B | |
| -18.35% | 20.77B | |
| -7.77% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- PPBT Stock
